PNCA
MCID: PNC035
MIFTS: 91

Pancreatic Cancer (PNCA)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 57 11 19 75 73 12 53 41 14 36 33
Pancreatic Carcinoma 57 11 73 53 43 14 16 71 33
Familial Pancreatic Carcinoma 19 58 28 5
Carcinoma of Pancreas 11 28 5 75
Pancreatic Carcinoma, Familial 11 75 71
Malignant Neoplasm of Pancreas 71 31 33
Pancreatic Neoplasm 11 16 71
Pancreatic Acinar Carcinoma 57 73
Familial Pancreatic Cancer 19 58
Neoplasm of the Pancreas 28 5
Cancer of the Pancreas 5 75
Pancreatic Tumor 11 53
Mixed Islet Cell with Exocrine Carcinoma of Unspecified Site 33
Malignant Neoplasm of Body of Pancreas 11
Malignant Neoplasm of Head of Pancreas 11
Malignant Neoplasm of Tail of Pancreas 11
Pancreatic Cancer, Susceptibility to 5
Hereditary Pancreatic Carcinoma 19
Pancreatic Carcinoma, Somatic 57
Carcinoma of Head of Pancreas 5
Hereditary Pancreatic Cancer 19
Exocrine Pancreas Carcinoma 11
Pancreatic Cancer, Somatic 57
Pancreatic Neoplasms 43
Ca Body of Pancreas 11
Ca Head of Pancreas 11
Ca Tail of Pancreas 11
Cancer, Pancreatic 38
Cancer of Pancreas 33
Pancreas Neoplasm 11
Pancreatic Tumors 14
Exocrine Cancer 11
Pnca 73

Characteristics:


Inheritance:

Pancreatic Cancer: Autosomal dominant 57
Familial Pancreatic Carcinoma: Autosomal dominant,Multigenic/multifactorial 58

Age Of Onset:

Familial Pancreatic Carcinoma: Adult 58

OMIM®:

57 (Updated 24-Oct-2022)
Miscellaneous:
may be seen with other forms of cancer in a family


Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 11 DOID:1793 DOID:4905
OMIM® 57 260350
NCIt 49 C3305 C3850
MESH via Orphanet 44 C535837
ICD10 via Orphanet 32 C25
UMLS via Orphanet 72 C2931038
Orphanet 58 ORPHA1333
MedGen 40 C0235974
UMLS 71 C0030297 C0153458 C0153459 more

Summaries for Pancreatic Cancer

MedlinePlus: 41 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include: Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary: Pancreatic Cancer, also known as pancreatic carcinoma, is related to breast cancer and pancreatic ductal adenocarcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Thrombin and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, exocrine pancreas and t cells, and related phenotypes are pancreatic adenocarcinoma and exocrine pancreatic insufficiency

GARD: 19 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by genetic changes in any of several genes. Individuals who carry a genetic change in one of these genes are often at an increased risk of other types of cancers as well. In many cases, inheritance of a predisposition to develop FPC is autosomal dominant. In some cases, is may be multifactorial.

OMIM®: 57 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350) (Updated 24-Oct-2022)

UniProtKB/Swiss-Prot: 73 A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Disease Ontology 11 Pancreatic cancer: An endocrine gland cancer located in the pancreas.

Pancreatic carcinoma: A pancreas cancer that derives from epithelial cells located in the exocrine pancreas.

Orphanet: 58 Familial pancreatic carcinoma is defined by the presence of pancreatic cancer (PC) in two or more first-degree relatives.

Wikipedia: 75 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1517)
# Related Disease Score Top Affiliating Genes
1 breast cancer 34.0 TSC1 TP53 STK11 SMAD4 RBBP8 PALB2
2 pancreatic ductal adenocarcinoma 33.8 TP53 SMAD4 MIR221 MIR21 MIR17 MIR155
3 dysplastic nevus syndrome 33.7 STK11 PALB2 BRCA2 BRCA1 ATM
4 pancreatic adenocarcinoma 33.6 TP53 SMAD4 KRAS BRCA2
5 adenocarcinoma 33.3 TP53 STK11 SMAD4 KRAS C11orf65 BRCA2
6 pancreatic ductal carcinoma 33.1 TP53 SMAD4 KRAS
7 colorectal cancer 33.0 TP53 STK11 SMAD4 PALB2 NBN MIR221
8 pancreatic signet ring cell adenocarcinoma 33.0 TP53 PALB2 KRAS
9 hereditary breast ovarian cancer syndrome 32.9 TP53 STK11 SMAD4 RBBP8 PALB2 NBN
10 malignant exocrine pancreas neoplasm 32.9 TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
11 ovarian cancer 32.9 TP53 SMAD4 RBBP8 PALB2 NBN MIR221
12 lynch syndrome 32.8 TP53 STK11 SMAD4 PALB2 MIR17 KRAS
13 lung cancer 32.8 TP53 STK11 SMAD4 PALB2 NBN MIR221
14 bap1 tumor predisposition syndrome 32.8 TSC1 TP53 STK11 SMAD4 PALB2 NBN
15 inherited cancer-predisposing syndrome 32.8 TSC1 TP53 STK11 SMAD4 PALB2 NBN
16 gastric cancer 32.6 TP53 STK11 SMAD4 MIR221 MIR21 MIR17
17 cholangiocarcinoma 32.5 TP53 SMAD4 MIR21 KRAS BRCA2 BRCA1
18 type 2 diabetes mellitus 32.5 TSC1 TP53 STK11 MIR221 MIR21 MIR17
19 ataxia-telangiectasia 32.4 TP53 STK11 RBBP8 NBN CHEK2 C11orf65
20 melanoma, cutaneous malignant 1 32.4 TP53 STK11 PALB2 MIR17 CHEK2 BRCA2
21 hepatocellular carcinoma 32.4 TP53 STK11 SMAD4 NBN MIR221 MIR21
22 deficiency anemia 32.3 TP53 SMAD4 PALB2 BRIP1 BRCA2 BRCA1
23 colonic benign neoplasm 32.3 TP53 SMAD4 PALB2 MIR21 KRAS CHEK2
24 esophageal cancer 32.3 TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
25 peripheral nervous system disease 32.2 TP53 MIR21 MIR17 KRAS BRCA1 ATM
26 body mass index quantitative trait locus 11 32.2 TP53 MIR221 MIR21 MIR17 MIR155 MIR10A
27 peutz-jeghers syndrome 32.2 TSC1 TP53 STK11 SMAD4 BRCA2
28 prostate cancer 32.2 TP53 SMAD4 NBN MIR221 MIR21 MIR17
29 fanconi anemia, complementation group a 32.2 TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
30 li-fraumeni syndrome 32.2 TP53 STK11 SMAD4 PALB2 KRAS CHEK2
31 in situ carcinoma 32.1 TP53 MIR17 KRAS BRCA2 BRCA1
32 lynch syndrome i 32.1 PALB2 CHEK2 BRCA2 BRCA1 ATM
33 bile duct cancer 32.1 TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
34 telangiectasis 32.1 TP53 SMAD4 NBN CHEK2 ATM
35 glioblastoma 32.1 TP53 MIR221 MIR21 MIR155 KRAS C11orf65
36 wilms tumor 1 32.0 TP53 PALB2 KRAS CHEK2 BRCA2 BRCA1
37 cystadenocarcinoma 32.0 TP53 MIR21 KRAS BRCA2 BRCA1
38 lung cancer susceptibility 3 32.0 TP53 STK11 SMAD4 MIR21 MIR17 KRAS
39 aplastic anemia 31.9 TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
40 biliary tract cancer 31.9 TP53 SMAD4 MIR221 MIR21 MIR17
41 bladder cancer 31.9 TSC1 TP53 MIR221 MIR21 MIR17 MIR10A
42 renal cell carcinoma, nonpapillary 31.8 TSC1 TP53 MIR221 MIR21 MIR17 MIR155
43 endometrial cancer 31.8 TP53 SMAD4 MIR21 KRAS BRCA2 BRCA1
44 ovarian cancer 1 31.8 PALB2 NBN BRIP1 BRCA2 BRCA1
45 breast ductal carcinoma 31.8 TP53 SMAD4 BRCA2 BRCA1
46 appendix adenocarcinoma 31.8 TP53 SMAD4 KRAS
47 breast-ovarian cancer, familial 1 31.8 PALB2 NBN BRIP1 BRCA2 BRCA1
48 leukemia, acute myeloid 31.8 TP53 MIR221 MIR21 MIR17 MIR155 MIR10A
49 rectum cancer 31.8 TP53 MIR221 MIR21 MIR17 KRAS
50 papillary adenocarcinoma 31.8 TP53 MIR221 MIR21 KRAS BRCA1

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intestinal Obstruction Pancreatic Agenesis 1
Pancreatitis, Hereditary Protein-Energy Malnutrition
Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Human phenotypes related to Pancreatic Cancer:

58 30 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pancreatic adenocarcinoma 58 30 Obligate (100%) Obligate (100%)
HP:0006725
2 exocrine pancreatic insufficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001738
3 back pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003418
4 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002027
5 anorexia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002039
6 chronic fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012432
7 weight loss 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001824
8 poor appetite 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004396
9 jaundice 58 30 Frequent (33%) Frequent (79-30%)
HP:0000952
10 lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0002716
11 intestinal pseudo-obstruction 58 30 Frequent (33%) Frequent (79-30%)
HP:0004389
12 extrahepatic cholestasis 58 30 Frequent (33%) Frequent (79-30%)
HP:0012334
13 functional intestinal obstruction 58 30 Frequent (33%) Frequent (79-30%)
HP:0005249
14 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002017
15 diabetes mellitus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000819
16 elevated hepatic transaminase 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002910
17 melanoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002861
18 breast carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003002
19 neoplasm of the liver 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002896
20 colon cancer 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003003
21 intermittent diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002254
22 hepatosplenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001433
23 ovarian carcinoma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025318
24 peritoneal abscess 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100592
25 neoplasm of the pancreas 30 HP:0002894
26 increased level of l-fucose in urine 30 HP:0410067

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma

Clinical features from OMIM®:

260350 (Updated 24-Oct-2022)

UMLS symptoms related to Pancreatic Cancer:


abdominal pain; constipation; diarrhea; dyspepsia; heartburn; icterus; nausea and vomiting; gastrointestinal gas; pruritus

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.39 KRAS
2 Decreased viability GR00055-A-2 10.39 KRAS
3 Decreased viability GR00055-A-3 10.39 KRAS
4 Decreased viability GR00106-A-0 10.39 KRAS
5 Decreased viability GR00221-A-1 10.39 ACVR1B KRAS
6 Decreased viability GR00221-A-2 10.39 ACVR1B BRCA1 CHEK2 KRAS TSC1
7 Decreased viability GR00221-A-3 10.39 BRCA1 CHEK2 TSC1
8 Decreased viability GR00221-A-4 10.39 ACVR1B CHEK2
9 Decreased viability GR00301-A 10.39 BRCA1 KRAS TSC1
10 Decreased viability GR00342-S-2 10.39 CHEK2
11 Decreased viability GR00381-A-1 10.39 KRAS
12 Decreased homologous recombination repair frequency GR00151-A-1 10.06 BRCA1 RBBP8
13 Decreased homologous recombination repair frequency GR00151-A-2 10.06 BRCA1 RBBP8
14 Decreased homologous recombination repair frequency GR00236-A-1 10.06 BRCA1 BRCA2 PALB2 RBBP8
15 Decreased homologous recombination repair frequency GR00236-A-2 10.06 BRCA1 BRCA2 PALB2 RBBP8
16 Decreased homologous recombination repair frequency GR00236-A-3 10.06 BRCA1 BRCA2 PALB2 RBBP8
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.05 BRCA1 BRCA2 NBN PALB2 STK11
18 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.05 ATM BRCA1 BRCA2 BRIP1 PALB2 STK11
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.05 ATM BRCA1 BRCA2 CHEK2 NBN TP53
20 Synthetic lethal with cisplatin GR00101-A-1 9.5 BRCA1 BRCA2 BRIP1
21 Decreased viability with cisplatin GR00101-A-4 9.43 BRCA1 BRCA2 BRIP1
22 Decreased viability after ionizing radiation GR00232-A-2 9.13 ATM BRCA1 BRCA2

MGI Mouse Phenotypes related to Pancreatic Cancer:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.34 ATM BRCA1 BRCA2 BRIP1 CHEK2 KRAS
2 nervous system MP:0003631 10.27 ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
3 endocrine/exocrine gland MP:0005379 10.21 ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
4 cellular MP:0005384 10.2 ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
5 embryo MP:0005380 10.18 ACVR1B ATM BRCA1 BRCA2 KRAS NBN
6 normal MP:0002873 10.13 ACVR1B BRCA1 BRCA2 KRAS MIR10A MIR155
7 immune system MP:0005387 10.03 ACVR1B ATM BRCA1 BRCA2 CHEK2 KRAS
8 digestive/alimentary MP:0005381 9.97 ACVR1B BRCA1 BRCA2 KRAS MIR155 SMAD4
9 reproductive system MP:0005389 9.93 ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
10 mortality/aging MP:0010768 9.8 ACVR1B ATM BRCA1 BRCA2 CHEK2 KRAS
11 integument MP:0010771 9.32 ACVR1B ATM BRCA1 BRCA2 KRAS PALB2

Drugs & Therapeutics for Pancreatic Cancer

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 695)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Desflurane Approved Phase 4 57041-67-5 42113
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
8
Etomidate Approved Phase 4 33125-97-2 667484
9
Meperidine Approved Phase 4 57-42-1 4058
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
12
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
13
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
14
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
15
Reviparin Approved, Investigational Phase 4 9041-08-1
16
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
17
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
18
Lutetium Lu 177 dotatate Approved, Investigational Phase 4 437608-50-9 76966897
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
20
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
21
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
22
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
25
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
26
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
27
Morphine Approved, Investigational Phase 4 57-27-2 5288826
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
29
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
30
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
31
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
32
Histamine Approved, Investigational Phase 4 51-45-6 774
33
L-Glutamine Approved, Investigational, Nutraceutical Phase 4 56-85-9 5961
34
D-Lysine Approved, Experimental, Nutraceutical Phase 4 923-27-3, 56-87-1 57449 5962
35
Polygeline Experimental Phase 4 66455-30-9
36 Parenteral Nutrition Solutions Phase 4
37 Soy Bean Phase 4
38 Blood Substitutes Phase 4
39 Plasma Substitutes Phase 4
40 Coagulants Phase 4
41 Fibrin Tissue Adhesive Phase 4
42 Dihydroxyphenylalanine Phase 4
43 Soybean oil, phospholipid emulsion Phase 4
44 Fat Emulsions, Intravenous Phase 4
45 Anesthetics, General Phase 4
46 Anesthetics, Inhalation Phase 4
47 Hypnotics and Sedatives Phase 4
48 Central Nervous System Stimulants Phase 4
49 GABA Modulators Phase 4
50 Nicotinic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 2910)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Unknown status NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
2 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
3 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Unknown status NCT03642093 Phase 4
4 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
5 Glycocalyx Levels in Patients Undergoing Pancreatectomy With Human Albumin 5% vs. Gelofusine Unknown status NCT04058236 Phase 4
6 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
7 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
8 Randomized Controlled Study to Evaluate the Effect of Thrombin-containing Collagen-based Hemostatic Matrix on Prevention of Pancreatic Fistula After Pancreatecomy Unknown status NCT04357483 Phase 4 flowable thrombin containing collagen hemostat matrix;thrombin coated L-dopa contained collagen patch
9 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
10 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
11 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
12 Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity Unknown status NCT04269369 Phase 4 5-Fluorouracil
13 A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Completed NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
14 Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment. Completed NCT00966277 Phase 4 Dalteparin
15 Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
16 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
17 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
18 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
19 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
20 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
21 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
22 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
23 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
24 Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial. Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
25 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
26 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
27 The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
28 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
29 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Completed NCT02335151 Phase 4 Desflurane
30 Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
31 Non-inferiority Study of Albumin-bound Paclitaxel Combined With Gemcitabine for Three Weeks Versus Four Weeks for First-line Inoperable Locally Advanced or Metastatic Pancreatic Cancer Recruiting NCT05035147 Phase 4 albumin-bound paclitaxel
32 Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial Recruiting NCT04025840 Phase 4 Dexamethasone
33 Endoscopic Ultrasound Guided Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Intractable Pain Due to Malignancy A Randomized Controlled Study Recruiting NCT04809935 Phase 4 98% dehydrated alcohol
34 Pre- vs. Postoperative Thromboprophylaxis in Pancreatic Surgery - a Prospective, Multicenter, Randomized Controlled Trial (PREPOSTEROUS Pancreas Trial) Recruiting NCT05245877 Phase 4 enoxaparin/tinzaparin/dalteparin
35 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
36 HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial Active, not recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
37 A Single-arm, Prospective Study to Evaluate the Efficacy and Safety of the Combination of Paclitaxel Liposome and S-1 as First-line Therapy in Treating Patients With Advanced Metastatic Pancreatic Cancer Not yet recruiting NCT04217096 Phase 4 Paclitaxel liposome;S-1
38 Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects Terminated NCT03859869 Phase 4 Pancrelipase;Placebo
39 An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
40 Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice Terminated NCT01887041 Phase 4
41 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
42 Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia Terminated NCT04155008 Phase 4 Dexamethasone;Dronabinol;Mirtazapine
43 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
44 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
45 A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer Withdrawn NCT04315311 Phase 4 CREON
46 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Withdrawn NCT03891979 Phase 4 Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
47 A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Unknown status NCT02506842 Phase 3 nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
48 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
49 A Prospective RCT Study of Distal Pancreatectomy Combined With Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail Unknown status NCT02117895 Phase 3
50 A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


docetaxel
Fluorouracil
Ifosfamide
irinotecan
Irinotecan hydrochloride
Octreotide
Octreotide Acetate
sunitinib
sunitinib malate
Tamoxifen
Tamoxifen Citrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 28 KRAS SMAD4 STK11 TP53
2 Neoplasm of the Pancreas 28
3 Familial Pancreatic Carcinoma 28

Anatomical Context for Pancreatic Cancer

Organs/tissues related to Pancreatic Cancer:

FMA: Pancreas, Exocrine Pancreas
MalaCards : Pancreas, T Cells, Lymph Node, Liver, Breast, Colon, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 45470)
# Title Authors PMID Year
1
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. 53 57 5
18762988 2008
2
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. 53 62 5
11248065 2001
3
DPC4 gene in various tumor types. 53 62 5
8653691 1996
4
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. 53 62 57
7726912 1994
5
p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. 53 62 5
8513440 1993
6
A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. 62 57
34559995 2021
7
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. 62 57
32376951 2020
8
Cysteine depletion induces pancreatic tumor ferroptosis in mice. 62 57
32241947 2020
9
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. 62 57
31221853 2019
10
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. 62 57
30996350 2019
11
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. 62 57
30918400 2019
12
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. 62 57
28099419 2017
13
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. 62 57
27732578 2016
14
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. 62 57
27213290 2016
15
Genomic analyses identify molecular subtypes of pancreatic cancer. 62 57
26909576 2016
16
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. 62 57
26168401 2015
17
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. 62 57
26106858 2015
18
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 62 57
25356972 2015
19
Whole genomes redefine the mutational landscape of pancreatic cancer. 62 57
25719666 2015
20
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. 62 57
23535601 2013
21
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. 62 57
23103869 2012
22
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 62 57
22368299 2012
23
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. 62 57
21436454 2011
24
mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. 62 5
21189378 2011
25
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. 62 57
20981101 2010
26
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. 62 57
20981102 2010
27
Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). 62 5
20581473 2010
28
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. 62 57
20101243 2010
29
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. 62 57
19648918 2009
30
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. 53 62 46
19714243 2009
31
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. 62 57
19460966 2009
32
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. 53 62 46
19407485 2009
33
Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. 62 57
15912495 2005
34
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. 62 57
14520413 2003
35
Progression model for pancreatic cancer. 62 57
10955772 2000
36
Inheritance of pancreatic cancer in pancreatic cancer-prone families. 62 57
10872424 2000
37
Characterization of a carboxy-terminal BRCA1 interacting protein. 62 5
9811458 1998
38
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. 62 57
9091646 1997
39
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. 62 57
7666917 1995
40
Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. 62 57
7616537 1995
41
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. 53 57
7845688 1995
42
Medical genetic study of eight pancreatic cancer-prone families. 62 57
7874567 1995
43
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. 62 5
8439212 1993
44
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. 62 57
3828965 1987
45
Pancreatic cancer in father and son. 62 57
67325 1977
46
Familial carcinoma of the pancreas. 62 57
1269168 1976
47
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study. 62 41
36107485 2022
48
The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. 57
31578522 2019
49
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. 57
27049944 2016
50
The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. 57
24859531 2014

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

5 (show top 50) (show all 126)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RBBP8 NM_002894.3(RBBP8):c.1009A>G (p.Lys337Glu) SNV Pathogenic
5824 rs121434388 GRCh37: 18:20572799-20572799
GRCh38: 18:22992836-22992836
2 STK11 NM_000455.5(STK11):c.108C>A (p.Tyr36Ter) SNV Pathogenic
7452 rs137853079 GRCh37: 19:1207020-1207020
GRCh38: 19:1207021-1207021
3 STK11 NM_000455.5(STK11):c.936del (p.Lys312fs) DEL Pathogenic
7454 rs397518443 GRCh37: 19:1222997-1222997
GRCh38: 19:1222998-1222998
4 ACVR1B NM_004302.5(ACVR1B):c.1159_1163del (p.Asp387fs) DEL Pathogenic
8227 rs387906389 GRCh37: 12:52380624-52380628
GRCh38: 12:51986840-51986844
5 ACVR1B NM_004302.5(ACVR1B):c.1262-502_1392+24del DEL Pathogenic
8228 rs1555162597 GRCh37: 12:52385141-52385797
GRCh38: 12:51991357-51992013
6 SMAD4 NM_005359.6(SMAD4):c.1072G>T (p.Gly358Ter) SNV Pathogenic
8536 rs121912576 GRCh37: 18:48591909-48591909
GRCh38: 18:51065539-51065539
7 SMAD4 NM_005359.6(SMAD4):c.1477G>C (p.Asp493His) SNV Pathogenic
8538 rs121912578 GRCh37: 18:48604655-48604655
GRCh38: 18:51078285-51078285
8 SMAD4 NM_005359.6(SMAD4):c.1543A>T (p.Arg515Ter) SNV Pathogenic
8539 rs121912579 GRCh37: 18:48604721-48604721
GRCh38: 18:51078351-51078351
9 TP53 NM_000546.6(TP53):c.105G>T (p.Leu35Phe) SNV Pathogenic
12371 rs121912661 GRCh37: 17:7579582-7579582
GRCh38: 17:7676264-7676264
10 STK11 NM_000455.5(STK11):c.716G>A (p.Trp239Ter) SNV Pathogenic
931293 rs730881975 GRCh37: 19:1220698-1220698
GRCh38: 19:1220699-1220699
11 POLD1 NM_002691.4(POLD1):c.3148del (p.Arg1050fs) DEL Pathogenic
1077091 GRCh37: 19:50920456-50920456
GRCh38: 19:50417199-50417199
12 BRIP1 NM_032043.3(BRIP1):c.1328_1334del (p.Cys443fs) DEL Pathogenic
1077092 GRCh37: 17:59876467-59876473
GRCh38: 17:61799106-61799112
13 CHEK2 NM_007194.4(CHEK2):c.908+1540_1095+330del DEL Pathogenic
1077093 GRCh37: 22:29092559-29097953
GRCh38: 22:28696571-28701965
14 BRCA2 NM_000059.4(BRCA2):c.1989del (p.Phe663fs) DEL Pathogenic
254495 rs886038068 GRCh37: 13:32910478-32910478
GRCh38: 13:32336341-32336341
15 BRCA2 NM_000059.4(BRCA2):c.7415dup (p.Cys2473fs) DUP Pathogenic
1077094 GRCh37: 13:32929402-32929403
GRCh38: 13:32355265-32355266
16 STK11 NM_000455.5(STK11):c.650del (p.Pro217fs) DEL Pathogenic
7453 rs397518442 GRCh37: 19:1220629-1220629
GRCh38: 19:1220630-1220630
17 KRAS NM_004985.5(KRAS):c.35G>T (p.Gly12Val) SNV Pathogenic
Pathogenic
12583 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
18 PALB2 NM_024675.4(PALB2):c.1652dup (p.Tyr551Ter) DUP Pathogenic
560017 rs1555461176 GRCh37: 16:23646214-23646215
GRCh38: 16:23634893-23634894
19 TP53 NM_000546.6(TP53):c.559+1G>A SNV Pathogenic
428908 rs1131691042 GRCh37: 17:7578370-7578370
GRCh38: 17:7675052-7675052
20 TP53 NM_000546.6(TP53):c.96+1G>T SNV Pathogenic
482212 rs1131691003 GRCh37: 17:7579699-7579699
GRCh38: 17:7676381-7676381
21 FANCE NM_021922.3(FANCE):c.929dup (p.Val311fs) DUP Pathogenic
655390 rs587778337 GRCh37: 6:35425714-35425715
GRCh38: 6:35457937-35457938
22 PALB2 NM_024675.4(PALB2):c.2167_2168del (p.Met723fs) DEL Pathogenic
136132 rs587776416 GRCh37: 16:23641307-23641308
GRCh38: 16:23629986-23629987
23 KRAS NM_004985.5(KRAS):c.458A>T (p.Asp153Val) SNV Pathogenic
12587 rs104894360 GRCh37: 12:25362838-25362838
GRCh38: 12:25209904-25209904
24 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic
12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
25 ATM NM_000051.4(ATM):c.2502dup (p.Val835fs) DUP Pathogenic
127351 rs587779822 GRCh37: 11:108137931-108137932
GRCh38: 11:108267204-108267205
26 BRIP1 NM_032043.3(BRIP1):c.2684_2687del (p.Val894_Ser895insTer) DEL Pathogenic
241642 rs760551339 GRCh37: 17:59763415-59763418
GRCh38: 17:61686054-61686057
27 CHEK2 NM_007194.4(CHEK2):c.846+4_846+7del DEL Pathogenic
216652 rs764884641 GRCh37: 22:29105987-29105990
GRCh38: 22:28709999-28710002
28 SMAD4 NM_005359.6(SMAD4):c.1236C>G (p.Tyr412Ter) SNV Pathogenic
24845 rs121912577 GRCh37: 18:48593485-48593485
GRCh38: 18:51067115-51067115
29 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
30 BRCA2 NM_000059.4(BRCA2):c.4525C>T (p.Gln1509Ter) SNV Pathogenic
51659 rs80358683 GRCh37: 13:32913017-32913017
GRCh38: 13:32338880-32338880
31 BRCA2 NM_000059.4(BRCA2):c.6408_6414del (p.Asn2137fs) DEL Pathogenic
52086 rs397507851 GRCh37: 13:32914898-32914904
GRCh38: 13:32340761-32340767
32 BRCA2 NM_000059.4(BRCA2):c.6405_6409del (p.Asn2135fs) DEL Pathogenic
38043 rs80359584 GRCh37: 13:32914894-32914898
GRCh38: 13:32340757-32340761
33 SMAD4 NM_005359.6(SMAD4):c.1082G>A (p.Arg361His) SNV Pathogenic
24832 rs377767347 GRCh37: 18:48591919-48591919
GRCh38: 18:51065549-51065549
34 SMAD4 NM_005359.6(SMAD4):c.1498A>G (p.Ile500Val) SNV Pathogenic
30150 rs281875322 GRCh37: 18:48604676-48604676
GRCh38: 18:51078306-51078306
35 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
36 SMAD4 NM_005359.6(SMAD4):c.1245_1248del (p.Asp415Glufs) DEL Pathogenic
142253 rs80338965 GRCh37: 18:48593491-48593494
GRCh38: 18:51067121-51067124
37 NBN NM_002485.5(NBN):c.657_661del (p.Lys219fs) DEL Pathogenic
6940 rs587776650 GRCh37: 8:90983442-90983446
GRCh38: 8:89971214-89971218
38 ATM, C11orf65 NM_000051.4(ATM):c.6095G>A (p.Arg2032Lys) SNV Pathogenic
181974 rs139770721 GRCh37: 11:108186638-108186638
GRCh38: 11:108315911-108315911
39 ATM, C11orf65 NM_000051.4(ATM):c.6096-9_6096-5del DEL Pathogenic
246092 rs879254095 GRCh37: 11:108186725-108186729
GRCh38: 11:108315998-108316002
40 ATM, C11orf65 NM_000051.4(ATM):c.7327C>T (p.Arg2443Ter) SNV Pathogenic
3036 rs121434220 GRCh37: 11:108200960-108200960
GRCh38: 11:108330233-108330233
41 PALB2 NM_024675.4(PALB2):c.509_510del (p.Arg170fs) DEL Pathogenic
126757 rs515726123 GRCh37: 16:23647357-23647358
GRCh38: 16:23636036-23636037
42 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs) DEL Pathogenic
128042 rs555607708 GRCh37: 22:29091857-29091857
GRCh38: 22:28695869-28695869
43 BRCA2 NM_000059.4(BRCA2):c.475G>A (p.Val159Met) SNV Pathogenic
51711 rs80358702 GRCh37: 13:32900287-32900287
GRCh38: 13:32326150-32326150
44 BRCA2 NM_000059.4(BRCA2):c.1813dup (p.Ile605fs) DUP Pathogenic
37762 rs80359306 GRCh37: 13:32907428-32907428
GRCh38: 13:32333283-32333284
45 BRCA2 NM_000059.4(BRCA2):c.3545_3546del (p.Gln1181_Phe1182insTer) DEL Pathogenic
37846 rs80359388 GRCh37: 13:32912036-32912037
GRCh38: 13:32337899-32337900
46 BRCA2 NM_000059.4(BRCA2):c.5073dup (p.Trp1692fs) DUP Pathogenic
37943 rs80359479 GRCh37: 13:32913565-32913565
GRCh38: 13:32339421-32339422
47 BRCA2 NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter) SNV Pathogenic
38099 rs80358972 GRCh37: 13:32930609-32930609
GRCh38: 13:32356472-32356472
48 BRCA2 NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His) SNV Pathogenic
52515 rs41293511 GRCh37: 13:32937506-32937506
GRCh38: 13:32363369-32363369
49 BRCA2 NM_000059.4(BRCA2):c.8755-1G>A SNV Pathogenic
38183 rs81002812 GRCh37: 13:32953453-32953453
GRCh38: 13:32379316-32379316
50 BRCA1 NM_007294.4(BRCA1):c.3770_3771del (p.Glu1257fs) MICROSAT Pathogenic
37546 rs80357579 GRCh37: 17:41243777-41243778
GRCh38: 17:43091760-43091761

Cosmic variations for Pancreatic Cancer:

8 (show top 50) (show all 630)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90142044 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 32
2 COSM84313984 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 32
3 COSM120694978 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 32
4 COSM121998482 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 32
5 COSM100986702 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 32
6 COSM92461094 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 32
7 COSM151944134 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
8 COSM151626276 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
9 COSM131023131 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
10 COSM111397487 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
11 COSM89661338 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
12 COSM151570633 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
13 COSM109739345 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
14 COSM151424813 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
15 COSM151524008 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
16 COSM149468859 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
17 COSM150576869 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
18 COSM106820556 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
19 COSM148672905 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
20 COSM112784932 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
21 COSM140844884 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
22 COSM151249776 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
23 COSM148061297 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
24 COSM138940468 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
25 COSM103090674 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 32
26 COSM139776915 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.868G>C p.G290R 18:51067035-51067035 32
27 COSM91386650 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 32
28 COSM103083840 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 32
29 COSM103089012 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 32
30 COSM139771981 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1309C>A p.L437I 18:51078405-51078405 32
31 COSM91381131 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 32
32 COSM139775765 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1312C>T p.Q438* 18:51078408-51078408 32
33 COSM91388156 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 32
34 COSM103029577 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.4325C>A p.S1442* 3:47120311-47120311 32
35 COSM149744235 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.-26C>A p.? 3:47120311-47120311 32
36 COSM137016084 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 32
37 COSM130781152 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 32
38 COSM88247526 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 32
39 COSM93826387 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5738C>A p.A1913D 6:117321280-117321280 32
40 COSM93857613 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 32
41 COSM107060151 RARA pancreas,NS,carcinoma,acinar carcinoma c.704T>A p.I235N 17:40354489-40354489 32
42 COSM98725155 RARA pancreas,NS,carcinoma,acinar carcinoma c.1043T>A p.I348N 17:40354489-40354489 32
43 COSM98729090 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 32
44 COSM107058842 RARA pancreas,NS,carcinoma,acinar carcinoma c.994G>T p.G332C 17:40356122-40356122 32
45 COSM86830145 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 32
46 COSM98724291 RARA pancreas,NS,carcinoma,acinar carcinoma c.1333G>T p.G445C 17:40356122-40356122 32
47 COSM98728207 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 32
48 COSM86828778 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 32
49 COSM98707819 RARA pancreas,NS,carcinoma,acinar carcinoma c.1270G>T p.G424C 17:40356122-40356122 32
50 COSM98708620 RARA pancreas,NS,carcinoma,acinar carcinoma c.980T>A p.I327N 17:40354489-40354489 32

Copy number variations for Pancreatic Cancer from CNVD:

6 (show top 50) (show all 15981)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss MFSD14A Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCA Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss S1PR1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss CENPS Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss PRMT6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5P Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss EEIG2 Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss ELAPOR1 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS1 Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TSC1 TP53 STK11 SMAD4 RBBP8 NBN
2
Show member pathways
13.81 ATM BRCA1 CHEK2 KRAS NBN SMAD4
3
Show member pathways
13.79 TP53 SMAD4 RBBP8 PALB2 NBN KRAS
4
Show member pathways
13.5 TP53 RBBP8 NBN CHEK2 BRIP1 BRCA2
5
Show member pathways
13.21 TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
6
Show member pathways
12.94 ATM BRCA1 BRIP1 CHEK2 NBN RBBP8
7
Show member pathways
12.93 ATM BRCA1 BRCA2 BRIP1 CHEK2 KRAS
8
Show member pathways
12.81 ATM BRCA1 BRIP1 CHEK2 NBN RBBP8
9
Show member pathways
12.78 RBBP8 PALB2 NBN BRIP1 BRCA2 BRCA1
10
Show member pathways
12.71 RBBP8 NBN BRCA2 BRCA1 ATM
11
Show member pathways
12.66 PALB2 NBN BRIP1 BRCA2 BRCA1 ATM
12
Show member pathways
12.64 TP53 NBN CHEK2 BRCA2 BRCA1 ATM
13
Show member pathways
12.47 TP53 SMAD4 NBN KRAS BRCA2 BRCA1
14
Show member pathways
12.46 TP53 KRAS CHEK2 ATM ACVR1B
15
Show member pathways
12.4 ATM BRCA1 CHEK2 NBN TP53
16 12.39 ATM BRCA1 BRCA2 BRIP1 CHEK2 NBN
17
Show member pathways
12.29 RBBP8 PALB2 NBN BRIP1 BRCA2 BRCA1
18
Show member pathways
12.24 TP53 SMAD4 CHEK2 ATM
19
Show member pathways
12.2 TP53 CHEK2 BRCA1 ATM
20
Show member pathways
12.15 TP53 NBN CHEK2 BRCA1 ATM
21 12.1 TSC1 TP53 STK11 KRAS
22 11.95 TP53 SMAD4 KRAS ATM
23
Show member pathways
11.85 TP53 NBN CHEK2 BRCA1 ATM
24 11.79 TSC1 TP53 STK11 SMAD4 KRAS
25
Show member pathways
11.79 TP53 RBBP8 NBN CHEK2 BRCA2 BRCA1
26 11.79 TSC1 TP53 STK11 SMAD4 KRAS CHEK2
27 11.78 TP53 SMAD4 NBN
28
Show member pathways
11.77 TP53 KRAS ACVR1B
29
Show member pathways
11.77 MIR221 MIR17 MIR155
30
Show member pathways
11.75 TP53 CHEK2 ATM
31 11.73 TP53 MIR221 MIR21 MIR17 ATM
32 11.69 RBBP8 BRCA1 ATM
33 11.65 TP53 BRCA1 ATM
34 11.65 TP53 SMAD4 MIR155 BRCA1
35
Show member pathways
11.62 TP53 RBBP8 NBN CHEK2 BRCA2 BRCA1
36 11.55 TP53 CHEK2 ATM
37 11.51 STK11 RBBP8 NBN CHEK2 ATM
38
Show member pathways
11.5 ATM CHEK2 TP53
39 11.47 TP53 CHEK2 BRCA1 ATM
40 11.47 TP53 NBN CHEK2 BRCA1 ATM
41 11.45 TSC1 TP53 STK11 SMAD4
42 11.34 TP53 CHEK2 ATM
43 11.33 TP53 BRCA1 ATM
44 11.3 TP53 KRAS ATM
45 11.23 TP53 RBBP8 NBN BRCA1 ATM
46 11.18 TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
47 11.09 TP53 BRCA1 ATM
48 10.83 NBN BRCA1 ATM
49 10.53 NBN ATM
50 10.52 TP53 CHEK2 ATM

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 10.03 TSC1 TP53 STK11 SMAD4 PALB2 BRCA2
2 nuclear ubiquitin ligase complex GO:0000152 9.62 BRCA2 BRCA1
3 BRCA1-B complex GO:0070532 9.46 BRIP1 BRCA1
4 BRCA1-C complex GO:0070533 9.43 RBBP8 NBN BRCA1
5 DNA repair complex GO:1990391 9.23 PALB2 BRCA2 BRCA1 ATM

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.38 TP53 MIR21 MIR17 KRAS BRCA1 ATM
2 regulation of cell cycle GO:0051726 10.33 ATM BRCA1 NBN STK11 TP53 TSC1
3 negative regulation of cell population proliferation GO:0008285 10.31 TSC1 TP53 STK11 SMAD4 MIR221 MIR21
4 in utero embryonic development GO:0001701 10.22 TP53 SMAD4 PALB2 NBN ACVR1B
5 negative regulation of cell growth GO:0030308 10.19 ACVR1B BRCA1 SMAD4 STK11 TP53
6 negative regulation of gene expression GO:0010629 10.18 TP53 MIR21 MIR17 MIR155 BRIP1 ACVR1B
7 somitogenesis GO:0001756 10.16 TP53 PALB2 ATM
8 regulation of signal transduction by p53 class mediator GO:1901796 10.15 STK11 CHEK2 ATM
9 nucleotide-excision repair GO:0006289 10.14 TP53 BRIP1 BRCA2
10 response to ionizing radiation GO:0010212 10.14 ATM BRCA1 STK11
11 cellular response to ionizing radiation GO:0071479 10.13 TP53 BRCA2 BRCA1
12 cell population proliferation GO:0008283 10.13 TSC1 TP53 SMAD4 NBN KRAS BRCA2
13 mitotic G2 DNA damage checkpoint signaling GO:0007095 10.12 NBN BRCA1 ATM
14 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 10.1 BRCA2 CHEK2 TP53
15 mitotic G2/M transition checkpoint GO:0044818 10.07 BRCA1 NBN RBBP8
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 10.06 TP53 CHEK2 ATM
17 DNA damage checkpoint signaling GO:0000077 10.06 NBN CHEK2 BRIP1 ATM
18 DNA repair GO:0006281 10.06 RBBP8 PALB2 NBN CHEK2 BRIP1 BRCA2
19 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10.05 CHEK2 BRCA2 BRCA1 ATM
20 signal transduction in response to DNA damage GO:0006975 10.04 CHEK2 ATM
21 signal transduction in response to DNA damage GO:0042770 10.04 CHEK2 ATM
22 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 10.03 STK11 SMAD4 MIR21
23 replicative senescence GO:0090399 10.03 TP53 CHEK2 ATM
24 double-strand break repair via homologous recombination GO:0000724 10.03 RBBP8 PALB2 NBN BRCA2 BRCA1 ATM
25 response to gamma radiation GO:0010332 10.02 TP53 CHEK2 BRCA2
26 cell cycle GO:0007049 10.01 ATM BRCA1 BRCA2 CHEK2 NBN RBBP8
27 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 10 TP53 CHEK2 BRCA2
28 positive regulation of epithelial to mesenchymal transition GO:0010718 9.98 SMAD4 MIR221 MIR21
29 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.97 TP53 SMAD4 MIR17
30 negative regulation of telomere capping GO:1904354 9.96 NBN ATM
31 female gonad development GO:0008585 9.91 SMAD4 BRCA2 ATM
32 DNA strand resection involved in replication fork processing GO:0110025 9.91 RBBP8 NBN BRCA1
33 cellular response to gamma radiation GO:0071480 9.91 TP53 MIR21 CHEK2 ATM
34 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.85 MIR221 MIR21 MIR17
35 chordate embryonic development GO:0043009 9.85 BRCA2 BRCA1
36 cellular response to DNA damage stimulus GO:0006974 9.83 TP53 STK11 RBBP8 PALB2 NBN CHEK2
37 homologous recombination GO:0035825 9.76 BRCA1 BRIP1 NBN RBBP8
38 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.66 MIR21 MIR17
39 positive regulation of metalloendopeptidase activity GO:1904685 9.65 MIR21 MIR17
40 negative regulation of interleukin-21 production GO:0032705 9.61 MIR221 MIR21
41 double-strand break repair GO:0006302 9.47 TP53 NBN CHEK2 BRIP1 BRCA2 BRCA1

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.76 TSC1 TP53 NBN ATM
2 mRNA 3'-UTR binding GO:0003730 9.43 TP53 MIR21 MIR17 MIR155 MIR10A
3 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR221 MIR21 MIR17 MIR155 MIR10A

Sources for Pancreatic Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....